European Heart Journal vs Hepatology: Which Journal Should You Choose?

EHJ wants the result to matter across cardiology. Hepatology wants the result to matter across liver disease.

That's the cleanest decision rule.

EHJ's editorial guidance emphasize cardiovascular breadth, ESC relevance, and field-level consequence. Hepatology's editorial guidance emphasize unmistakable liver focus, mechanistic or translational depth, and the need to connect clearly to real hepatology questions.

If your manuscript feels most persuasive when written in cardiology language, EHJ is usually closer. If the paper only really comes alive when written in liver-disease language, Hepatology is usually the better call.

EHJ wins when the cardiovascular story is the central story.

That usually means:

• cardiovascular outcomes are the primary endpoints that matter
• the practical audience is cardiologists
• the liver or metabolic context is important, but not the main home field
• the paper could plausibly influence broad cardiovascular interpretation or management

Examples:

• MASLD studies where the true consequence is cardiovascular-risk prediction or management
• cirrhosis-related hemodynamic or arrhythmia work when cardiology practice is the key audience
• cross-specialty registry studies where the main implication is for cardiovascular care

EHJ's editorial guidance also make clear that the journal wants more than a specialty intersection. It wants field-wide cardiovascular significance.

Hepatology wins when the liver story remains central.

That includes:

• liver-disease studies where cardiovascular outcomes are important but still secondary to hepatology understanding
• mechanistic work in liver disease with translational value
• MASLD, fibrosis, inflammation, cirrhosis, transplantation, or liver-oncology work that belongs naturally to hepatology readers
• manuscripts where the best conversation is among hepatologists, not general cardiologists

Hepatology's editorial guidance keep stressing a strong liver identity. That matters here because many crossover papers are attractive scientifically but still have a very obvious home field once you strip away the prestige question.

Hepatology expects unmistakable liver focus

Hepatology submission's editorial guidance is explicit that the journal wants work that AASLD editors can connect immediately to real hepatology problems. If the manuscript needs too much cardiology framing to explain itself, that's a clue it may belong elsewhere.

EHJ expects broader cardiovascular consequence

The EHJ material repeatedly emphasizes general cardiovascular relevance and strong consequences for cardiology readers. A liver-context paper can fit there, but only if the cardiovascular implication is broad enough.

Hepatology can carry deeper mechanistic liver narratives

That matters because some cardio-liver papers are really about liver biology, metabolic disease, or disease-pathway interpretation. Those papers often get weaker, not stronger, when stripped down into a general cardiology frame.

EHJ won't rescue a niche liver paper

A strong liver paper with some cardiovascular spillover doesn't become an EHJ paper just because heart-related outcomes are present. The cardiology consequence still has to dominate.

• the paper is fundamentally cardiovascular
• cardiologists are the main audience
• the main implication is about cardiovascular risk, management, or outcomes
• the manuscript feels strongest when written as a cardiology paper

That's the EHJ lane.

• the paper is fundamentally about liver disease
• hepatologists are the main audience
• the manuscript depends on liver-specific context to be convincing
• the strongest consequence is inside hepatology, even if cardiovascular outcomes are important

That's the Hepatology lane.

MASLD and cardiometabolic overlap

This is probably the most common real overlap. If the paper is mainly about cardiovascular risk or cardiovascular outcome prediction, EHJ becomes more plausible. If it's mainly about liver disease progression, liver-pathway biology, or hepatology management, Hepatology is usually the cleaner fit.

Cirrhosis and cardiovascular complications

These papers can sound broad, but the audience question still decides the case. If the work is mainly for hepatologists dealing with cirrhotic physiology, portal complications, or liver-specific risk, Hepatology usually wins. If the work should change how cardiologists interpret or manage patients with major cardiovascular implications, EHJ gets stronger.

Transplant and outcome papers

Again, ask who needs the result most. If the result primarily informs transplant-hepatology decision-making, Hepatology is likely better. If it primarily informs cardiovascular interpretation across broader practice, EHJ becomes more realistic.

This can be a real cascade, but only when the paper was mispositioned.

A manuscript rejected by EHJ can move to Hepatology if the work is genuinely liver-led and the rejection reflects insufficient breadth for general cardiology rather than weak science.

The reverse route is less common. A paper rejected by Hepatology because it lacks a sufficiently strong liver identity usually doesn't become an EHJ paper unless the cardiovascular consequence was truly under-framed.

EHJ punishes organ-specific framing that never becomes broad cardiology

If the manuscript remains heavily liver-defined all the way through, EHJ often looks like the wrong room.

Hepatology punishes papers that borrow liver context but aren't really hepatology papers

If the manuscript only touches liver disease but the result isn't actually about a hepatology question, the fit weakens quickly.

EHJ punishes inflated claims of breadth

Editors can usually tell when a cross-specialty paper is trying to sound more generally cardiovascular than it really is.

Hepatology punishes thin translational payoff

The journal can take mechanistic and translational work, but it still wants clear field-level importance and a reason hepatologists should care.

A strong EHJ first page makes the cardiovascular consequence obvious before the liver context becomes detailed.

A strong Hepatology first page makes the liver-disease consequence obvious before any cardiovascular crossover detail takes over the narrative.

If only one of those first pages feels natural, that usually tells you the better journal.

Try finishing one of these sentences:

• "this changes what cardiologists should do or how they stratify risk" points toward European Heart Journal
• "this changes what hepatologists should do or how they interpret liver disease" points toward Hepatology

That sentence test is basic, but it usually reveals the true center of gravity.

Send to European Heart Journal first if:

1. the manuscript is fundamentally cardiovascular
2. the practical readership is cardiology
3. cardiovascular consequence is the main reason the paper matters
4. liver context supports the story, but doesn't define it

Send to Hepatology first if:

1. the manuscript is fundamentally liver focused
2. the practical readership is hepatology
3. liver biology or liver care is the main reason the paper matters
4. cardiovascular outcomes are important, but still sit inside a hepatology story